Glaukos Corporation (NYSE:GKOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Glaukos Corporation (NYSE:GKOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02(b). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 6, 2018, Jonathan T. Silverstein informed Glaukos Corporation (the “Company”) that he intends to resign from the Company’s Board of Directors (the “Board”) effective March 14, 2018. Mr. Silverstein, a Class II director whose term of service expires at the Company’s annual meeting of shareholders in 2020, has served on the Board since 2008.


About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.